Bionano Genomics Inc. (NASDAQ: BNGO) is 138.64% higher on its value in year-to-date trading and has touched a low of $0.25 and a high of $15.69 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BNGO stock was last observed hovering at around $7.75 in the last trading session, with the day’s loss setting it -0.4% off its average median price target of $14.00 for the next 12 months. It is also 51.0% off the consensus price target high of $15.00 offered by 3 analysts, but current levels are 47.5% higher than the price target low of $14.00 for the same period.
Currently trading at $7.35, the stock is -14.58% and -27.48% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 13.79 million and changing -5.16% at the moment leaves the stock 130.38% off its SMA200. BNGO registered 1542.46% gain for a year compared to 6-month gain of 1148.51%. The firm has a 50-day simple moving average (SMA 50) of $10.05 and a 200-day simple moving average (SMA200) of $4.37.
The stock witnessed a -24.46% loss in the last 1 month and extending the period to 3 months gives it a 942.55%, and is -18.78% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.76% over the week and 13.20% over the month.
Bionano Genomics Inc. (BNGO) has around 147 employees, a market worth around $2.09B and $8.50M in sales. Distance from 52-week low is 2840.00% and -53.15% from its 52-week high. The company has generated returns on investments over the last 12 months (-75.10%).
Bionano Genomics Inc. (BNGO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Bionano Genomics Inc. (BNGO) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Bionano Genomics Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.04 with sales reaching $3.07M over the same period.The EPS is expected to grow by 80.20% this year, but quarterly earnings will post 99.60% year-over-year. Quarterly sales are estimated to grow 169.30% in year-over-year returns.
Bionano Genomics Inc. (BNGO) Top Institutional Holders
27 institutions hold shares in Bionano Genomics Inc. (BNGO), with 158.84k shares held by insiders accounting for 0.06% while institutional investors hold 5.64% of the company’s shares. The shares outstanding are 278.66M, and float is at 276.46M with Short Float at 8.60%. Institutions hold 5.64% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 7.13 million shares valued at $21.97 million. The investor’s holdings represent 2.56% of the BNGO Shares outstanding. As of Dec 30, 2020, the second largest holder is Pura Vida Investments, LLC with 2.1 million shares valued at $6.47 million to account for 0.75% of the shares outstanding. The other top investors are Geode Capital Management, LLC which holds 0.94 million shares representing 0.34% and valued at over $2.91 million, while Bank Julius Baer & Co. Ltd, Zurich holds 0.31% of the shares totaling 0.85 million with a market value of $2.62 million.
Bionano Genomics Inc. (BNGO) Insider Activity
A total of 1 insider transactions have happened at Bionano Genomics Inc. (BNGO) in the last six months, with sales accounting for 0 and purchases happening 1 times.